| Citation: |
WANG Xueli, MA Hongyan. Pharmacodynamics of Doxorubicin Long-circulating Thermo-sensitive Liposomes Combined with Radiofrequency Thermotherapy[J]. Cancer Research on Prevention and Treatment, 2016, 43(5): 350-354. DOI: 10.3971/j.issn.1000-8578.2016.05.007
|
To investigate the tumor inhibiting effects and relative pharmacodynamics of doxorubicin long-circulating thermo-sensitive liposomes (DOX-LCTSLs) combined with radiofrequency (RF) thermotherapy on HeLa tumor-bearing nude mice.
A HeLa tumor-bearing mice model was established and the mice were divided into six groups: Control, RF, DOX, DOX-LCTSLs, DOX+RF and DOX-LCTSLs+RF groups. DOX concentration in the organs and tumor were detected at 0.5, 1, 4 and 12 h to determine the biodistribution. During the treatment, the living conditions of the nude mice were observed, the tumor volume was measured every other day and the tumor inhibition rate was calculated. After the treatment, the organs and tumor were stained by HE, and the morphological changes of the cells were observed. TUNEL stained method was used to detect cell apoptosis effect.
Biodistribution results indicated that DOX concentration of DOX-LCTSLs group in the heart was significantly lower than that of DOX group; the tumor inhibition rate of DOX-LCTSLs+RF group was 82.14% which had significant difference compared with DOX and DOX+RF groups (P＜0.05). HE staining results of DOX-LCTSLs group demonstrated that it had no obvious toxicity to major organs, however, the tumor cells appeared irregular and karyolysis; TUNEL apoptosis detection showed that the tumor tissues appeared significant apoptosis after the treatment on DOX-LCTSLs+RF group.
Compared with other treatment groups, DOX-LCTSLs group have the obvious thermal control release effect and low toxicity. With RF thermotherapy treatment, DOX-LCTSLs could significantly enhance the anti-tumor activity.
| [1] |
Bernstein D, Burridge P. Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: a new window into personalized medicine[J]. Prog Pediatr Cardiol, 2014, 37(1-2): 23-7.
|
| [1] |
Koyama T, Mikami Y, Saga T, et al. Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation[J]. Abdom Imaging, 2007, 32(6): 784-795.
|
| [2] |
Xu H, Zhang W, Li Y, et al. The bifunctional liposomes constructed by poly(2-ethyl-oxazoline)-cholesteryl methyl carbonate: an effectual approach to enhance liposomal circulation time, pHsensitivity and endosomal escape[J]. Pharm Res, 2014, 31(11): 30 38-50.
|
| [2] |
Chen S, Paruligiani G. Meta—analysis of BRCAl and BRCA2 penetrance[J]. J Clin Oneol, 2007, 25(11): 1329-1333.
|
| [3] |
Paoli EE, Ingham ES, Zhang H, et al. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes[J]. J Control Release, 2014, 178: 108-17.
|
| [3] |
Vollebergh MA, Lips EH, Nederlof PM, et al. Genomic patterns resembling BRCAl-and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy[J]. Breast Cancer Res, 2014, 16(3): R47.
|
| [4] |
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCAl or BRCA2 mutations detected in case series unselected for family history: a combined analysis of22 studies[J]. Am J Hum Genet, 2003, 72(5): 1117- 1130.
|
| [4] |
Song X, Zhang R, Liang C, et al. Nano-assemblies of J-aggregates based on a NIR dye as a multifunctional drug carrier for combination cancer therapy[J]. Biomaterials, 2015, 57: 84-92.
|
| [5] |
Patra S, Roy E, Karfa P, et al. Dual-responsive polymer coated superparamagnetic nanoparticle for targeted drug delivery and hyperthermia treatment[J]. ACS Appl Mater Interfaces, 2015, 7( 17): 9235-46.
|
| [5] |
李向东.C-erbB-2、ER和PR在乳腺癌中的表达与预后意义[J].现代肿瘤医学，2006，14(3): 289.
|
| [6] |
Nemani KV, Ennis RC, Griswold KE, et al. Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E-coli for enzyme-prodrug therapy[J]. J Biotechnol, 2015, 203: 32-40.
|
| [6] |
LI Xiangdong. Expression and prognostic significance of C-erbB-2, ER and PR in breast cancer[J]. Modern Oncology Medicine, 2006, 14(3): 289.
|
| [7] |
Verma S, Joy AA, Rayson D, et al. HER story: the next chapter in HER-2-directed therapy for advanced breast cancer[J]. Oncologist, 2013, 18(11): 1153-1166.
|
| [7] |
Nishimura S, Saeki H, Nakanoko T, et al. Hyperthermia Combined with Chemotherapy for Patients with Residual or Recurrent Oesophageal Cancer After Definitive Chemoradiotherapy[J]. Anticancer Res, 2015, 35(4): 2299-303.
|
| [8] |
Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014, 32(19):2078-2099.
|
| [8] |
Wang L, Zhang P, Shi J, et al. Radiofrequency-triggered tumortargeting delivery system for theranostics application[J]. ACS Appl Mater Interfaces, 2015, 7(10): 5736-47.
|
| [9] |
Verri E, Guglielmini P, Puntoni M, et al. NER2/neu oncoprotein overexpression in epitheliaI ovarian cancer: evaluation of its prevalence and prognosticsignificance[J]. Oncology, 2005, 68: 154-161.
|
| [9] |
Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes[J]. Anti-cancer drugs, 2015, 26(3): 241-58.
|
| [10] |
何以丰，徐丛剑，冯令达.HER2与上皮性卵巢癌术后生存率相关性的Meta分析[J].中国循证医学杂志，2007，7(6): 420.
|
| [10] |
Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma[J]. Oncology (Williston Park), 2007, 21(12): 1503-8.
|
| [11] |
Hegyi G, Szasz O, Szasz A. Oncothermia: a new paradigm and promising method in cancer therapies[J]. Acupunct Electro Research, 2013, 38(3-4): 161-97.
|
| [11] |
HE Yifeng, XU Congjian, FENG Lingda. Meta analysis of the correlation between HER2 and the survival rate of epithelial ovarian cancer[J]. Chinese Journal of Evidence-based Medicine, 2007, 7(6): 420.
|
| [12] |
Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group[J]. Ann Oncol, 2004, 15(1):104.
|
| [12] |
Wang L, Shi J, Jia X, et al. NIR-/pH-Responsive drug delivery of functionalized single-walled carbon nanotubes for potential application in cancer chemo-photothermal therapy[J]. Pharm Res, 20 13, 30(11): 2757-71.
|
| [13] |
Riener EK, Arnold N, Kommoss F, et al. The prognostic and predictive valw of immunohistochemically detected,Her-2 overexpression in 361 patients with ovarian cancer;a multicenter study[J]. Gynecol Oncol, 2004, 95(1):89.
|
| [13] |
Shi J, Wang L, Zhang J, et al. A tumor-targeting near-infrared laser-triggered drug delivery system based on GO@Ag nanoparticles for chemo-photothermal therapy and X-ray imaging[J]. Biomaterials, 2014, 35(22): 5847-61.
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: